| Pharmaceutical Information |
| Drug Name |
Tapentadol |
| Drug ID |
BADD_D02115 |
| Description |
Opioid analgesic for treatment of moderate to severe pain. FDA approved on Nov 20, 2008. |
| Indications and Usage |
The immediate-release formulation of tapentadol is indicated for the relief of moderate to severe acute pain. The long-acting formulation serves as a continuous, around-the-clock analgesic that is indicated for the relief of moderate to severe chronic pain or neuropathic pain associated with diabetic peripheral neuropathy. |
| Marketing Status |
approved |
| ATC Code |
N02AX06 |
| DrugBank ID |
DB06204
|
| KEGG ID |
D06007
|
| MeSH ID |
D000077432
|
| PubChem ID |
9838022
|
| TTD Drug ID |
D0K4MH
|
| NDC Product Code |
Not Available |
| UNII |
H8A007M585
|
| Synonyms |
Tapentadol | 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)phenol | Nucynta | Tapentadol Hydrochloride |
|
| Chemical Information |
| Molecular Formula |
C14H23NO |
| CAS Registry Number |
175591-23-8 |
| SMILES |
CCC(C1=CC(=CC=C1)O)C(C)CN(C)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
